Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares US Real Estate ETF
IYR
|
+$947M |
| 2 |
Tesla
TSLA
|
+$608M |
| 3 |
Microsoft
MSFT
|
+$444M |
| 4 |
Accenture
ACN
|
+$409M |
| 5 |
iShares MSCI Emerging Markets ETF
EEM
|
+$396M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRH
CRH
|
+$2.06B |
| 2 |
Texas Instruments
TXN
|
+$1.92B |
| 3 |
Meta Platforms (Facebook)
META
|
+$1.81B |
| 4 |
Starbucks
SBUX
|
+$1.42B |
| 5 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$1,000M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.52% |
| 2 | Financials | 7.13% |
| 3 | Consumer Discretionary | 6.46% |
| 4 | Healthcare | 5.43% |
| 5 | Communication Services | 5.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4401
Empire Petroleum
EP
$102M
| $114K | ﹤0.01% |
21,776
+17,249
| +381% | +$88.8K |
|
4402
CervoMed
CRVO
$23.3M
| $113K | ﹤0.01% |
7,748
+5,919
| +324% | +$91.7K |
|
4403
M-tron Industries
MPTI
$359M
| $113K | ﹤0.01% |
+2,712
| New | +$94K |
|
4404
Outlook Therapeutics
OTLK
$194M
| $112K | ﹤0.01% |
20,943
+18,249
| +677% | +$134K |
|
4405
VanEck Pharmaceutical ETF
PPH
$970M
| $111K | ﹤0.01% |
1,173
-3,263
| -74% | -$310K |
|
4406
C&F Financial
CFFI
$272M
| $111K | ﹤0.01% |
1,904
+1,264
| +198% | +$68.5K |
|
4407
HireQuest
HQI
$188M
| $111K | ﹤0.01% |
7,837
+5,818
| +288% | +$78.3K |
|
4408
Consumer Portfolio Services
CPSS
$208M
| $111K | ﹤0.01% |
11,794
+8,828
| +298% | +$82.2K |
|
|
NOTE
4409
DELISTED
FiscalNote
NOTE
| $110K | ﹤0.01% |
7,191
+5,472
| +318% | +$95.2K |
|
4410
Strawberry Fields REIT
STRW
$196M
| $110K | ﹤0.01% |
8,697
+6,535
| +302% | +$75K |
|
4411
SES AI
SES
$200M
| $110K | ﹤0.01% |
171,860
+126,763
| +281% | +$132K |
|
|
EEX
4412
DELISTED
Emerald Holding
EEX
| $110K | ﹤0.01% |
21,977
+14,244
| +184% | +$76.2K |
|
4413
DLH Holdings
DLHC
$71M
| $110K | ﹤0.01% |
11,716
+8,782
| +299% | +$92.5K |
|
4414
Crexendo
CXDO
$221M
| $109K | ﹤0.01% |
+23,583
| New | +$102K |
|
4415
Aemetis
AMTX
$110M
| $109K | ﹤0.01% |
47,496
+34,816
| +275% | +$97.6K |
|
|
SACH
4416
Sachem Capital Corp
SACH
$38.6M
| $109K | ﹤0.01% |
+43,129
| New | +$109K |
|
4417
ALX Oncology
ALXO
$262M
| $108K | ﹤0.01% |
59,502
+42,185
| +244% | +$157K |
|
4418
iShares Russell Mid-Cap Growth ETF
IWP
$19.8B
| $108K | ﹤0.01% |
920
-271,820
| -100% | -$30.4M |
|
|
AKYA
4419
DELISTED
Akoya BioSciences
AKYA
| $107K | ﹤0.01% |
39,472
+30,095
| +321% | +$73.5K |
|
4420
Suzano
SUZ
$10.4B
| $107K | ﹤0.01% |
10,650
-14
| -0.1% | -$137 |
|
|
SUNS
4421
Sunrise Realty Trust
SUNS
$108M
| $106K | ﹤0.01% |
+7,392
| New | +$94.8K |
|
4422
Century Therapeutics
IPSC
$395M
| $106K | ﹤0.01% |
61,945
+45,797
| +284% | +$89.7K |
|
|
MAPS
4423
DELISTED
WM TECHNOLOGY INC A
MAPS
| $106K | ﹤0.01% |
121,510
+33,153
| +38% | +$33K |
|
4424
Pharvaris
PHVS
$2.37B
| $106K | ﹤0.01% |
+5,700
| New | +$104K |
|
4425
Valhi
VHI
$391M
| $104K | ﹤0.01% |
3,129
+2,389
| +323% | +$55.6K |
|
Similar funds
Barclays's Q3 2024 Portfolio in Review
As of Q3 2024, Barclays held 5,593 positions worth $377B, up 15% from $327B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Barclays deployed $31.3B of net new capital in Q3 2024, opening 785 new positions and adding to 2,954 existing holdings. Its largest new stake was Smurfit Westrock: 3,460,710 shares worth $171M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 22% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was CRH, an estimated $2.06B trimmed.
- Barclays's largest Q3 2024 buy was Smurfit Westrock: 3,460,710 shares worth $171M.
- Barclays added most to iShares US Real Estate ETF in Q3 2024, an estimated $947M increase.
- Barclays's biggest Q3 2024 reduction was CRH, cutting an estimated $2.06B.
- Barclays fully exited Equitrans Midstream Corporation Common Stock in Q3 2024, selling an estimated $51.3M.
- Barclays's ten largest holdings make up 41% of its $377B portfolio in Q3 2024.
- Barclays opened 785 new positions and closed 322 in Q3 2024.
- Barclays's portfolio value rose 15% quarter-over-quarter to $377B.
Based on Barclays's 13F filing for Q3 2024, filed 15 Nov 2024.